Profil Financier
Dilip Shanghvi occupe actuellement le rang #99 du classement mondial StarFortune (secteur santé & biotech). Fortune nette estimée : $25.3 B (+$487 sur 24h).
The son of a pharmaceuticals distributor, Dilip Shanghvi borrowed $200 from his father to start Sun Pharmaceutical Industries in 1983 to make psychiatric drugs.
The company is India's most valuable listed pharma outfit and gets two-thirds of its $6.1 billion annual revenue from overseas markets.
He grew Sun through a series of acquisitions, the biggest of which was the 2014 purchase of scandal-tainted rival Ranbaxy Laboratories for $4 billion.
Sun Pharma acquired U.S. skin cancer drug maker Checkpoint Therapeutics in May 2025 for $355 million.
In February 2025, his son Aalok was appointed as chief operating officer of Sun Pharma.
Photos of Shanghvi's family deity, Shrinathji, adorn Sun's factories and offices.
Shanghvi 's favorite cuisine is south Indian.
In 2023, Sun Pharma completed the $576 million acquisition of U.S.-based Concert Pharmaceuticals.